ALS TDI - ALS Therapy Development Institute. The world's most advanced research laboratory dedicated to ALS.
animal STUDIES
General Information
Treatment:metformin
Treatment Class:Small Molecule
Model:G93A High Copy
Study Start Date:07/16/2009
Study Completed Date:11/28/2009
Rationale:Possible rationales: An AGEs formation inhibitor, acts via activation of AMP-activated protein kinase (AMPK), a cellular sensor of energy status.
Average NL/NR Male and Female
Average Body Weight Male and Female
Survival Male and Female
Study Design
Controlled for Litter:male: female:
Controlled for Gender:
General Information
Treatment:metformin
Treatment Class:Small Molecule
Model:G93A High Copy
Study Start Date:07/17/2009
Study Completed Date:11/29/2009
Rationale:Possible rationales: An AGEs formation inhibitor, acts via activation of AMP-activated protein kinase (AMPK), a cellular sensor of energy status.
Average NL/NR Male and Female
Average Body Weight Male and Female
Survival Male and Female
Study Design
Controlled for Litter:male: female:
Controlled for Gender:








Email Print Digg MySpace Favorites Twitter
Facebook Delicious Google Live Stumble More
 
Home | What is ALS | Research | Get Involved | News | Forums | About Us | Contact | Site Map
© 2010 ALS THERAPY DEVELOPMENT INSTITUTE
ALS TDI is a 501(c)(3) registered nonprofit organization.

Security Seal Privacy Verified Seal Business Verified Seal Certified by Trust Guard